These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24680169)

  • 1. Recent advances in antidotes for direct oral anticoagulants: their arrival is imminent.
    Lauw MN; Coppens M; Eikelboom JW
    Can J Cardiol; 2014 Apr; 30(4):381-4. PubMed ID: 24680169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct oral anticoagulants: new drugs and new concepts.
    Levy JH; Spyropoulos AC; Samama CM; Douketis J
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1333-51. PubMed ID: 25523529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs).
    Hussain SS; Tyroch AH; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):76-81. PubMed ID: 27215215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
    Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma.
    Wienhold J; Rayatdoost F; Schöchl H; Grottke O
    Curr Opin Anaesthesiol; 2024 Apr; 37(2):101-109. PubMed ID: 38390922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Reversal of Direct Oral Anticoagulants in Animal Models.
    Honickel M; Akman N; Grottke O
    Shock; 2017 Aug; 48(2):144-158. PubMed ID: 28471371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal Agents for the Direct Oral Anticoagulants.
    Ansell JE
    Hematol Oncol Clin North Am; 2016 Oct; 30(5):1085-98. PubMed ID: 27637309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors.
    Nafee T; Aslam A; Chi G; Pahlavani S; Nimri D; Kuchkuntla AR; Talib U; Michalak N; Daaboul Y; Korjian S; Gallo A; Gibson CM
    Expert Rev Cardiovasc Ther; 2017 Apr; 15(4):237-245. PubMed ID: 28282497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Historical Perspective on the Reversal of Anticoagulants.
    Salter B; Crowther M
    Semin Thromb Hemost; 2022 Nov; 48(8):955-970. PubMed ID: 36055273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
    Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):547-53. PubMed ID: 17762530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antidotes for the direct oral anticoagulants: What news?
    Galliazzo S; Donadini MP; Ageno W
    Thromb Res; 2018 Apr; 164 Suppl 1():S119-S123. PubMed ID: 29703468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants.
    Ansell JE
    J Thromb Thrombolysis; 2016 Feb; 41(2):248-52. PubMed ID: 26449414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.
    Kalathottukaren MT; Haynes CA; Kizhakkedathu JN
    Drug Deliv Transl Res; 2018 Aug; 8(4):928-944. PubMed ID: 28741113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative use of prothrombin complex concentrates.
    Colomina MJ; Díez Lobo A; Garutti I; Gómez-Luque A; Llau JV; Pita E
    Minerva Anestesiol; 2012 Mar; 78(3):358-68. PubMed ID: 22357373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality and safety issues of direct oral anticoagulants in the emergency department.
    Cervellin G; Benatti M; Bonfanti L; Lippi G
    Semin Thromb Hemost; 2015 Apr; 41(3):348-54. PubMed ID: 25839867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of Factor Eight Inhibitor Bypassing Activity for direct oral anticoagulant-related hemorrhage reversal.
    Engelbart JM; Zepeski A; Galet C; Policeni B; Skeete DA; Faine BA
    Am J Emerg Med; 2019 Feb; 37(2):214-219. PubMed ID: 29802004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation.
    Sarma A; Giugliano RP
    Hosp Pract (1995); 2015; 43(5):258-67. PubMed ID: 26559852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A short review of ciraparantag in perspective of the currently available anticoagulant reversal agents.
    Leentjens J; Middeldorp S; Jung C
    Drug Discov Today; 2022 Oct; 27(10):103332. PubMed ID: 35933085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants.
    Liew A; Eikelboom JW; O'Donnell M; Hart RG
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S34-44. PubMed ID: 23790596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature.
    Shaw JR; Castellucci LA; Siegal D; Carrier M
    J Thromb Haemost; 2023 Mar; 21(3):433-452. PubMed ID: 36696204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.